The talks on drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that ...
Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback